Finland
ChainPeptides Oy, headquartered in Finland and founded in 2022, is pioneering integrated solutions for Diabetic Foot Ulcers (DFU) with their novel Chain Smart PlasterTM. As diabetes affects an estimated 589M people globally with projections reaching 853M by 2050, the need for advanced DFU treatments is urgent.
The startup is addressing a critical market void by tackling infections caused by drug-resistant pathogens like MRSA and Pseudomonas aeruginosa. Their proprietary antimicrobial peptides, demonstrating significant efficacy in various studies, aim to curb infection progression and reduce amputation risks, capturing a segment of the global DFU treatment market, projected to grow at a CAGR of 6.3% to US$ 14.36 billion by 2032.
Currently in a Seed Round, ChainPeptides Oy seeks funding to further its collaboration with European healthcare institutions, leveraging nanoparticles and biosensors for superior treatment efficacy and real-time infection detection, heralding a new era in diabetic care.